SSXB3 inhibitors pertain to a class of chemical compounds that are specifically designed to interact with the SSXB3 receptor, a protein or enzyme that plays a role in a particular biochemical pathway within an organism. The exact nature of SSXB3, including its function and significance, derives from extensive biochemical and pharmacological research. These inhibitors are synthesized through a meticulous process of chemical engineering, wherein researchers aim to craft molecules that can bind to the SSXB3 receptor with high affinity and specificity. This binding process is critical, as it directly influences the activity of the receptor, modulating its role in the associated biochemical cascade. The design of SSXB3 inhibitors is typically informed by the structural biology of the target receptor, utilizing techniques such as X-ray crystallography or NMR spectroscopy to elucidate the receptor's 3D conformation.
The development of SSXB3 inhibitors involves a complex interplay of various scientific disciplines, including organic chemistry, molecular biology, and computational modeling. Organic chemists contribute by creating novel chemical entities or altering existing ones to improve their interactions with the SSXB3 receptor. These modifications can pertain to changes in the inhibitors' molecular size, shape, or electronic distribution, which are all critical factors that can affect how the inhibitor fits into the receptor's binding site. Molecular biologists may assist by expressing and purifying the SSXB3 receptor, thereby providing a platform for testing the binding efficacy of the inhibitors. Computational modelers use advanced algorithms and simulations to predict how an inhibitor might interact with the receptor at an atomic level, often providing insights that can expedite the refinement of the inhibitor's structure. The culmination of these efforts is the production of a set of SSXB3 inhibitors that are characterized by their ability to bind to the designated receptor with the intended level of inhibition, without exerting an effect on similar receptors in the organism, thus ensuring specificity in their mechanism of action.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
This is a potent phosphoinositide 3-kinase (PI3K) inhibitor. PI3K is upstream of Akt signaling, which can regulate the nuclear import of SSXB3. Wortmannin, by inhibiting PI3K, could decrease Akt activation, thereby reducing SSXB3 nuclear import. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to Wortmannin. It suppresses PI3K activity leading to a reduction in Akt phosphorylation and downstream signaling, which is crucial for SSXB3 localization and function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which is involved in protein synthesis and cell growth. Inhibition of mTOR could lead to a decrease in the synthesis of proteins, including SSXB3. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. SSXB3 could be dependent on MAPK signaling for its activation, and thus PD98059 could reduce SSXB3 function by inhibiting this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which may be involved in the phosphorylation and activity of SSXB3. By inhibiting JNK, SP600125 could reduce SSXB3 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
As a p38 MAPK inhibitor, SB203580 could affect the activity of SSXB3 if SSXB3 function is modulated by p38 MAPK-dependent phosphorylation. This inhibition would reduce SSXB3 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of ERK1/2. If SSXB3 activity requires ERK1/2 signaling, then U0126 would lead to decreased SSXB3 function. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
Dactolisib is a dual inhibitor of PI3K and mTOR. It could decrease SSXB3 activity by inhibiting the signaling pathways that regulate SSXB3 synthesis and function. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the activation of Akt. Since Akt signaling might regulate SSXB3 activity, triciribine could result in lowered SSXB3 activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor, which could lead to cell cycle arrest. If SSXB3 is involved in cell cycle progression, its activity could be reduced by palbociclib through inhibition of cell cycle-related signaling. | ||||||